Market capitalization | $673.25m |
Enterprise Value | $500.84m |
P/B ratio (TTM) P/B ratio | 3.52 |
Cash position | $194.37m |
P/E forward | negative |
P/S forward | 8.04 |
EV/Sales forward | 5.98 |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
5 Analysts have issued a Ceribell forecast:
5 Analysts have issued a Ceribell forecast:
Dec '24 |
+/-
%
|
||
Revenue | 19 19 |
-
|
|
Gross Profit | 16 16 |
-
|
|
EBITDA | -13 -13 |
-
|
EBIT (Operating Income) EBIT | -13 -13 |
-
|
Net Profit | -13 -13 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ceribell, Inc. is a commercial-stage medical technology company, which focuses on transforming the diagnosis and management of patients with serious neurological conditions. Its products include Point-of-Care EEG, which enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies, Clarity, an AI algorithm that interprets EEG in real-time, providing bedside alerts and continuous monitoring for status epilepticus, and EEG Portal, which makes it easy to remotely review EEG in real-time with pre-annotated EEG insights. The company was founded by Xing Juan Chao, Josef Parvizi, and Chris Chafe on August 29, 2014 and is headquartered in Sunnyvale, CA.
Head office | United States |
CEO | Xing Chao |
Employees | 281 |
Website | www.ceribell.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.